![Full Text of PDF](img/ico_pdf_full.gif)
Article in Japanese
A case of pulmonary Mycobacterium avium disease treated with liposomal amikacin inhalation therapy before surgical resection
Hideto Oshitaa Takashi Kumadab Koji Yoshiokaa Yasuhiko Ikegamia Eiji Miyaharab Naoki Yamaokaa
aDepartment of Respiratory Medicine, Federation of National Public Service and Affiliated Personnel Mutual Aid Associations, Yoshijima Hospital
bDepartment of Respiratory Surgery, Federation of National Public Service and Affiliated Personnel Mutual Aid Associations, Yoshijima Hospital
The patient was a 45-year-old woman whose mother had died of pulmonary Mycobacterium avium complex (MAC) disease. The patient was treated with the standard antibiotic therapy for pulmonary M. avium disease for 9 months. However, her sputum cultures remained positive for M. avium. She received liposomal amikacin inhalation therapy for 5 months. Negative conversion of sputum culture and improvement in imaging findings were observed. Thoracoscopic lingulectomy of the residual lesion was performed, and her sputum cultures remained negative for M. avium after the surgery. This case suggests that liposomal amikacin inhalation therapy is effective as a preoperative antibiotic therapy.
Nontuberculous mycobacteriosis Pulmonary Mycobacterium avium complex disease Amikacin liposome inhalation suspension (ALIS) Preoperative antibiotic therapy Surgical resection
Received 14 Sep 2022 / Accepted 4 Nov 2022
AJRS, 12(1): 19-23, 2023